A role for soluble ST2 in vascular remodeling associated with obesity in rats

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Martínez Martínez, Ernesto ^a   Miana, María ^a   Jurado López, Raquel ^a   Rousseau, Elodie ^b   Rossignol, Patrick ^b   Zannad, Faiez ^b   Cachofeiro, Victoria ^a   López Andrés, Natalia ^b,c  

^a SCHOOL OF MEDICINE   (Spain)

^b UNIVERSITÉ DE LORRAINE   (France)

^c Atención Primaria Y Promoción de La Salud   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALS; AORTA; BIOLOGICAL MARKERS; BLOOD PRESSURE; BLOOD VESSELS; BODY WEIGHT; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; FIBROSIS; INFLAMMATION; INTERLEUKINS; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OBESITY; RATS; RECEPTORS, INTERLEUKIN-1; SIGNAL TRANSDUCTION;

EID: 84893122874     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079176     Document Type: Article

References (35)

1. Mokdad AH, Serdula MK, Dietz WH, Bowman BA, Marks JS, et al. (1999) The spread of the obesity epidemic in the United States, 1991-1998. JAMA 282: 1519-1522. (Pubitemid 29504044)
2. Korner J, Aronne LJ (2003) The emerging science of body weight regulation and its impact on obesity treatment. J Clin Invest 111: 565-570. (Pubitemid 36278571)
3. Zebekakis PE, Nawrot T, Thijs L, Balkestein EJ, Heijden-Spek J, et al. (2005) Obesity is associated with increased arterial stiffness from adolescence until old age. J Hypertens 23: 1839-1846. (Pubitemid 41830424)
4. Folli F, Kahn CR, Hansen H, Bouchie JL, Feener EP (1997) Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100: 2158-2169. (Pubitemid 27500137)
5. Wallis MG, Wheatley CM, Rattigan S, Barrett EJ, Clark AD, et al. (2002) Insulin-mediated hemodynamic changes are impaired in muscle of Zucker obese rats. Diabetes 51: 3492-3498. (Pubitemid 35403455)
6. Tominaga S (1989) A putative protein of a growth specific cDNA from BALB/c-3T3 cells is highly similar to the extracellular portion of mouse interleukin 1 receptor. FEBS Lett 258: 301-304.
7. Werenskiold AK, Hoffmann S, Klemenz R (1989) Induction of a mitogenresponsive gene after expression of the Ha-ras oncogene in NIH 3T3 fibroblasts. Mol Cell Biol 9: 5207-5214. (Pubitemid 19275992)
8. Tago K, Noda T, Hayakawa M, Iwahana H, Yanagisawa K, et al. (2001) Tissue distribution and subcellular localization of a variant form of the human ST2 gene product, ST2V. Biochem Biophys Res Commun 285: 1377-1383. (Pubitemid 32912936)
9. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie AN, et al. (2007) IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J Clin Invest 117: 1538-1549. (Pubitemid 46871338)
10. Palmer G, Lipsky BP, Smithgall MD, Meininger D, Siu S, et al. (2008) The IL-1 receptor accessory protein (AcP) is required for IL-33 signaling and soluble AcP enhances the ability of soluble ST2 to inhibit IL-33. Cytokine 42: 358-364.
11. Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, et al. (2005) IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity 23: 479-490. (Pubitemid 41587888)
12. Miller AM, Liew FY (2011) The IL-33/ST2 pathway-A new therapeutic target in cardiovascular disease. Pharmacol Ther 131: 179-186.
13. Li H, Tago K, Io K, Kuroiwa K, Arai T, et al. (2000) The cloning and nucleotide sequence of human ST2L cDNA. Genomics 67: 284-290. (Pubitemid 30651029)
14. Bartunek J, Delrue L, Van DF, Muller O, Casselman F, et al. (2008) Nonmyocardial production of ST2 protein in human hypertrophy and failure is related to diastolic load. J Am Coll Cardiol 52: 2166-2174.
15. Demyanets S, Kaun C, Pentz R, Krychtiuk KA, Rauscher S, et al. (2013) Components of the interleukin-33/ST2 system are differentially expressed and regulated in human cardiac cells and in cells of the cardiac vasculature. J Mol Cell Cardiol. In press.
16. Zeyda M, Wernly B, Demyanets S, Kaun C, Hammerle M, et al. (2012) Severe obesity increases adipose tissue expression of interleukin-33 and its receptor ST2, both predominantly detectable in endothelial cells of human adipose tissue. Int J Obes (Lond). In press.
17. Coglianese EE, Larson MG, Vasan RS, Ho JE, Ghorbani A, et al. (2012) Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study. Clin Chem 58: 1673-1681.
18. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, et al. (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107: 721-726. (Pubitemid 36222600)
19. Shimpo M, Morrow DA, Weinberg EO, Sabatine MS, Murphy SA, et al. (2004) Serum levels of the interleukin-1 receptor family member ST2 predict mortality and clinical outcome in acute myocardial infarction. Circulation 109: 2186-2190. (Pubitemid 38625395)
20. Maeso R, Rodrigo E, Munoz-Garcia R, Navarro-Cid J, Ruilope LM, et al. (1998) Chronic treatment with losartan ameliorates vascular dysfunction induced by aging in spontaneously hypertensive rats. J Hypertens 16: 665-672. (Pubitemid 28230555)
21. Calvier L, Miana M, Reboul P, Cachofeiro V, Martinez-Martinez E, et al. (2013) Galectin-3 mediates aldosterone-induced vascular fibrosis. Arterioscler Thromb Vasc Biol 33: 67-75.
22. Laurent S, Boutouyrie P, Lacolley P (2005) Structural and genetic bases of arterial stiffnes. Hypertension 45: 1050-1055. (Pubitemid 40770302)
23. Redon J, Cifkova R, Laurent S, Nilsson P, Narkiewicz K, et al. (2009) Mechanisms of hypertension in the cardiometabolic syndrome. J Hypertens 27: 441-451.
24. Grassi G, Seravalle G, Scopelliti F, Dell'Oro R, Fattori L, et al. (2010) Structural and functional alterations of subcutaneous small resistance arteries in severe human obesity. Obesity (Silver Spring) 18: 92-98.
25. Sutton-Tyrrell K, Newman A, Simonsick EM, Havlik R, Pahor M, et al. (2001) Aortic stiffness is associated with visceral adiposity in older adults enrolled in the study of health, aging, and body composition. Hypertension 38: 429-433. (Pubitemid 34225678)
26. Zieman SJ, Melenovsky V, Kass DA (2005) Mechanisms, pathophysiology, and therapy of arterial stiffness. Arterioscler Thromb Vasc Biol 25: 932-943. (Pubitemid 40627836)
27. Ruiz-Ortega M, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J (2007) TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74: 196-206.
28. de las HN, Ruiz-Ortega M, Miana M, Ruperez M, Sanz-Rosa D, et al. (2007) Interactions between aldosterone and connective tissue growth factor in vascular and renal damage in spontaneously hypertensive rats. J Hypertens 25: 629-638.
29. Intengan HD, Schiffrin EL (2001) Vascular remodeling in hypertension: roles of apoptosis, inflammation, and fibrosis. Hypertension 38: 581-587.
30. Miller AM, Xu D, Asquith DL, Denby L, Li Y, et al. (2008) IL-33 reduces the development of atherosclerosis. J Exp Med 205: 339-346. (Pubitemid 351281600)
31. Ciccia F, Alessandro R, Rizzo A, Raimondo S, Giardina A, et al. (2013) IL-33 is overexpressed in the inflamed arteries of patients with giant cell arteriti. Ann Rheum Dis 72: 258-264.
32. van Greevenbroek MM, Schalkwijk CG, Stehouwer CD (2013) Obesityassociated low-grade inflammation in type 2 diabetes mellitus: causes and consequences. Neth J Med 71: 174-187.
33. Ky B, French B, McCloskey K, Rame JE, McIntosh E, et al. (2011) Highsensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circ Heart Fail 4: 180-187.
34. Mildner M, Storka A, Lichtenauer M, Mlitz V, Ghannadan M, et al. (2010) Primary sources and immunological prerequisites for sST2 secretion in humans. Cardiovasc Res 87: 769-777.
35. McLaren JE, Michael DR, Salter RC, Ashlin TG, Calder CJ, et al. (2010) IL-33 reduces macrophage foam cell formation. J Immunol 185: 1222-1229.